Literature DB >> 17018895

Isolation and expansion of allogeneic myeloma-specific interferon-gamma producing T cells for adoptive immunotherapy.

Darina Ocadlikova1, L Zahradova, L Kovarova, M Penka, J Zaloudik, T Buchler, R Hajek, J Michalek.   

Abstract

Adoptive immunotherapy is a promising approach in the treatment of multiple myeloma. We have tested the identification, separation, and expansion of allogeneic myeloma-specific T cells in vitro. Irradiated myeloma cell line ARH 77 has been used to stimulate allogeneic CD4(+) and CD8(+) T lymphocytes. Activated myeloma-specific T cells that produced interferon-gamma were isolated using immunomagnetic beads and further expanded in vitro to numbers of up to 400 x 106 T cells. Specificity of the T lymphocytes was tested using a 5-(6-)carboxyfluoresceine diacetate succinimidyl ester (CFSE)-based cytotoxicity test. This study demonstrates the feasibility of identification and isolation of tumor-specific T cells from allogeneic donors that can be expanded in vitro to numbers useful for clinical applications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17018895     DOI: 10.1385/MO:23:3:377

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.738


  22 in total

Review 1.  Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution.

Authors:  A B Lyons
Journal:  J Immunol Methods       Date:  2000-09-21       Impact factor: 2.303

2.  Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation.

Authors:  Scott R Solomon; Stephan Mielke; Bipin N Savani; Aldemar Montero; Laura Wisch; Richard Childs; Nancy Hensel; John Schindler; Victor Ghetie; Susan F Leitman; Thao Mai; Charles S Carter; Roger Kurlander; Elizabeth J Read; Ellen S Vitetta; A John Barrett
Journal:  Blood       Date:  2005-04-07       Impact factor: 22.113

3.  Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10.

Authors:  R D Brown; B Pope; A Murray; W Esdale; D M Sze; J Gibson; P J Ho; D Hart; D Joshua
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

4.  Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes.

Authors:  Toshiaki Hayashi; Teru Hideshima; Masaharu Akiyama; Noopur Raje; Paul Richardson; Dharminder Chauhan; Kenneth C Anderson
Journal:  Blood       Date:  2003-04-24       Impact factor: 22.113

5.  A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

Authors:  M Attal; J L Harousseau; A M Stoppa; J J Sotto; J G Fuzibet; J F Rossi; P Casassus; H Maisonneuve; T Facon; N Ifrah; C Payen; R Bataille
Journal:  N Engl J Med       Date:  1996-07-11       Impact factor: 91.245

6.  Clinical-scale selective depletion of alloreactive T cells using an anti-CD25 immunotoxin.

Authors:  J Michálek; R H Collins; E S Vitetta
Journal:  Neoplasma       Date:  2003       Impact factor: 2.575

Review 7.  Treatment of multiple myeloma.

Authors:  Bart Barlogie; John Shaughnessy; Guido Tricot; Joth Jacobson; Maurizio Zangari; Elias Anaissie; Ron Walker; John Crowley
Journal:  Blood       Date:  2003-09-11       Impact factor: 22.113

8.  Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning.

Authors:  Choon Kee Lee; Ashraf Badros; Bart Barlogie; Christopher Morris; Maurizio Zangari; Athanasios Fassas; Frits van Rhee; Michele Cottler-Fox; Joth Jacobson; Raymond Thertulien; Firas Muwalla; Syed Mazher; Elias Anaissie; Guido Tricot
Journal:  Exp Hematol       Date:  2003-01       Impact factor: 3.084

Review 9.  Dendritic cell vaccines in the treatment of multiple myeloma: advances and limitations.

Authors:  Tomas Büchler; Roman Hajek
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

10.  Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality.

Authors:  Nicolaus Kröger; Herbert Gottfried Sayer; Rainer Schwerdtfeger; Michael Kiehl; Arnon Nagler; Helmut Renges; Tatjana Zabelina; Boris Fehse; Francis Ayuk; Georg Wittkowsky; Norbert Schmitz; Axel Rolf Zander
Journal:  Blood       Date:  2002-08-08       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.